Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 20/20 | 0.81 |
| ▸ | GUCY1A2 | P33402 | 20/20 | 0.81 |
| ▸ | GUCY1A1 | Q02108 | 20/20 | 0.81 |
| ▸ | GUCY1B1 | Q02153 | 20/20 | 0.81 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15087456 | 0.90 | GUCY1B2 (1.00) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL30513569 | 0.90 | GUCY1B2 (1.00) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL18596916 | 0.87 | GUCY1B2 (0.63) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL15087454 | 0.85 | GUCY1B2 (0.63) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL17481626 | 0.85 | GUCY1B2 (0.80) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL23031924 | 0.84 | GUCY1B2 (0.80) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL17621249 | 0.81 | GUCY1B2 (0.69) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL17621251 | 0.80 | GUCY1B2 (0.73) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL18866734 | 0.79 | GUCY1B2 (0.61) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL18596947 | 0.79 | GUCY1B2 (0.57) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030874-B2 | Processes and intermediates for the preparation of soluble guanylate cyclase stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030874-B2 | Processes and intermediates for the preparation of soluble guanylate cyclase stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230339928-A1 | NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339928-A1 | NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| EP-4249469-A2 | NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3737679-B1 | NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11708361-B2 | Processes and intermediates for the preparation of soluble guanylate cyclase stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708361-B2 | Processes and intermediates for the preparation of soluble guanylate cyclase stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220024909-A1 | NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20210053962-A1 | NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024909-A1 | NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A2, GUCY1B2, GUCY1B1 | GUCY1B2 2/4885GUCY1A2 1/4885GUCY1A1 4/4885 |
| US-11708361-B2 | Processes and intermediates for the preparation of soluble guanylate cyclase stimulators | GUCY1A2, GUCY1B1, GUCY1B2 | GUCY1B2 3/4885GUCY1A2 1/4885GUCY1A1 4/4885 |
| US-20210053962-A1 | NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A2, GUCY1B1, GUCY1B2 | GUCY1B2 3/4885GUCY1A2 1/4885GUCY1A1 4/4885 |
| US-12030874-B2 | Processes and intermediates for the preparation of soluble guanylate cyclase stimulators | GUCY1A2, GUCY1B1, GUCY1B2 | GUCY1B2 3/4885GUCY1A2 1/4885GUCY1A1 4/4885 |
| US-20230339928-A1 | NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A2, GUCY1B2, GUCY1B1 | GUCY1B2 2/4885GUCY1A2 1/4885GUCY1A1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.